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Abstract
Brugada syndrome is a life-threatening, inherited arrhythmia disorder associated with autosomal
dominant mutations in SCN5A, the gene encoding the human cardiac Na+ channel  subunit
(Nav1.5). Here, we characterized the biophysical properties of a novel Brugada syndrome-
associated Nav1.5 mutation, A551T, identified in a proband who was successfully resuscitated from
an episode of ventricular fibrillation with sudden collapse. Whole-cell currents through wild-type
(WT) Nav1.5 and mutant (A551T) channels were recorded and compared in the human embryonic
kidney cell line HEK293T transfected with SCN5A cDNA and SCN1B cDNA, using the patch-
clamp technique. Current density was decreased in the A551T mutant compared to the WT. In
addition, the A551T mutation reduced Nav1.5 activity by promoting entry of the channel into fast
inactivation from the closed state, thereby shifting the steady-state inactivation curve by -5 mV.
Furthermore, when evaluated at -90 mV, the resting membrane potential, but not at the
conventionally used -120 mV, both the percentage, and rate, of channel recovery from inactivation
were reduced in the mutant. These results suggest that the DI-DII linker may be involved in the
stability of inactivation gating process. This study supports the notion that a reduction in Nav1.5
channel function is involved in the pathogenesis of Brugada syndrome. The structural-functional
study of the Nav1.5 channel advances our understanding of its pathophysiolgocial function.
Background
Brugada syndrome is a life-threatening, inherited arrhyth-
mia disorder associated with autosomal dominant muta-
tions in SCN5A [1-4], the gene encoding the human
cardiac Na+ channel  subunit (Nav1.5) [5], which con-
tains four homologous domains, each composed of six
membrane-spanning segments, linked by cytoplasmic
linkers. Brugada syndrome is characterized by a distinctive
ST-segment elevation in the V1–V3 leads of the ECG that
reflects abnormal electrical forces in the right ventricle [6],
which are linked to SCN5A mutations causing reduced
Nav1.5 function [5]. The discovery of SCN5A mutations
in families with Brugada syndrome was first reported in
1998 [1]. Subsequently, several others have been identi-
fied and functional studies on these mutations have been
performed using a heterologous expression system [2,7-
11]. Despite many studies, the molecular and cellular
mechanisms underlying Brugada syndrome are not com-
pletely known [12,13].
Nav1.5 channels initiate action potentials in most cardiac
myocytes and thus play a critical role in cardiac excitabil-
ity and impulse propagation. Some Brugada syndrome-
related SCN5A mutations produce lose-of-function
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defects by completely disrupting Nav1.5 function [1] or
by reducing ion permeation or membrane surface expres-
sion [14], whereas others elicit a functional deficit by
accelerating the rates of fast and slow inactivation
[7,9,14,15]. The identification of the various clinical phe-
notypes resulting from SCN5A mutations is critical for
optimal patient management. In addition, an understand-
ing of the structural-functional relationship of the Nav1.5
channel may result in the development of new therapies
for heart diseases.
In this study, we describe the functional properties of an
Nav1.5 mutation, A551T, identified in a patient with
Brudaga syndrome, whose resting ECG showed a coved-
type ST elevation in the right precordial leads [16]. We
found that the A551T mutation decreased the Na+ current
density, enhanced entry into fast inactivation from the
closed state, and decreased channel recovery from inacti-
vation. The decreased Nav1.5 activity caused by the A551T
mutation supports the hypothesis that a reduction in
Nav1.5 function is involved in the pathogenesis of Bru-
gada syndrome.
Materials and methods
Genetic analysis
Genomic DNA was purified from peripheral blood lym-
phocytes using Gentra Blood DNA isolation kit (Gentra,
USA) after obtaining informed consent from the patient.
All exons of SCN5A were amplified by polymerase chain
reaction (PCR) and screened for mutations using the dide-
oxynucleotide chain termination method with fluorescent
dideoxynucleotides on an ABI DNA sequencer (PE
Applied-Biosystem, USA). The investigation conforms to
the principles outlined in the Declaration of Helsinki.
This study was approved by the ethics review board of the
National Taiwan University Hospital (NTUH
9400000202).
Cell culture
HEK293T cells are the Human Embryonic Kidney 293
cells, transformed by expression of the large T antigen
from SV40 virus that inactivates pRb. These cells were cul-
tured in Dulbecco's modified Eagle's medium (Sigma
Chemical, St. Lois, MO, USA) containing 10% fetal
bovine serum (Life Technologies, Paisley, Scotland) and
1% penicillin-streptomycin at 37°C in a humidified
atmosphere containing 5% CO2. Cells were plated on
poly-L-lysine-coated No. 1 glass cover slips (42 mm) (Carl
Zeiss, Inc., Germany) and transiently transfected with
SCN5A-CFP (0.75 g) and SCN1B-YFP (0.75 g) using
LipofectAMINE 2000 (Invitrogen Co., Carlsbad, CA,
USA). Cells expressing both proteins, identified by double
fluorescence, were selected for experiments.
Electrophysiological recordings
Whole-cell currents were recorded at room temperature
(21–24°C) using the patch-clamp technique [17,18] and
an Axopatch 200B amplifier (Axon Instruments, Foster
City, CA, USA). The extracellular solution (pH 7.4, titrated
with NaOH) contained (in mM): NaCl 140, CsCl 10,
CaCl2 2, MgCl2 1, glucose 5, and HEPES 10. The intracel-
lular solution (pH 7.2, titrated with CsOH) contained (in
mM): CsF 110, CsCl 10, NaF 10, EGTA 11, CaCl2 1, MgCl2
1, Na2ATP 2, and HEPES 10. The command voltage pulses
were controlled and data acquired using pClamp6 soft-
ware (Axon Instruments, Foster City, CA, USA). Series
resistance was compensated by  80%. The membrane
potential was not corrected for liquid junction potential (-
6.7 mV) because the junction potential was cancelled
when calculating Vm  differences between WT and
mutants. The plots of voltage dependent steady state acti-
vation and inactivation were fitted by Boltzmann equa-
tion:
where V0.5 is the voltage at which sodium current is half-
maximally activated, and k was the slope factor. Time con-
stants of inactivation were obtained by fitting the decay-
ing phase of current trace with a biexponential equation:
The recovery from inactivation at -120 mV was fit by a
biexponential equation:
The recovery from inactivation at -90 mV was fit by a
mono exponential equation:
The voltage-dependence of all activation and inactivation
recordings was recorded 5 minutes after establishing the
whole-cell configuration. Data were sampled at 20 kHz
and filtered at 5 kHz with the exception of those obtained
during the P1 pulse, which were sampled at 6.67 kHz.
Site-directed mutagenesis
Mutations were constructed using a PCR-based technique
using overlapping primers containing the desired altered
sequences. The G at base#1651 of the SCN5A gene was
changed to A in the A551T mutant; the C at base#1652 of
the SCN5A gene was changed to T in the A551V mutant;
the C at base#1652 of the SCN5A gene was changed to A
in the A551E mutant. The mutated cDNAs were
11 05 /[ exp( )/ ], . +− VV k (1)
At fA C t s C *exp( / ) ( )*exp( / ) . −+ − − −+  1
(2)
At f A t s *[ exp( / )] ( )*[ exp( / )]. 11 1 −− + − −− 
(3)
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sequenced using an ABI Prism™ dRhodamine Terminator
Cycle Sequencing Ready Reaction Kit (PE Applied Biosys-
tems, Foster City, CA, USA) to confirm the mutation.
Sequence-based identification of phosphorylation sites
Potential phosphorylation sites were predicted using the
NetPhos 2.0 server at http://www.cbs.dtu.dk/services/Net
Phos/.
Data analysis
Results are presented as the mean ± SEM with sample sizes
(n) indicating the number of cells from which the data
were obtained Statistical significance was assessed using
Student's t test. A p value less than 0.05 was considered
statistically significant.
Results
Clinical studies
The proband, a 45-year-old male patient, was successfully
resuscitated from an episode of ventricular fibrillation
with sudden collapse. After the episode, a 12-lead ECG
was performed without a drug challenge test and showed
ST segment elevation in the right precordial leads (Fig 1).
In V2, the QRS complex showed a typical Brugada type 1
pattern with a coved-shape ST-T segment, while a saddle-
back ST-T pattern (Brugada type 2 pattern) was observed
in V3. An implantable cardioverter defibrillator was
implanted to prevent further attacks. Sequence analysis
showed a heterozygous missense single nucleotide
replacement 1651G>A, which resulted in an amino acid
change from alanine to threonine at position 551 (abbre-
viated as A551T) in the DI-DII linker of the Nav1.5 chan-
nel [16].
Electrophysiological characterization of the wild-type and 
A551T Nav1.5 channels
Next, we compared the electrophysiological properties of
WT and A551T channels heterologously expressed in
HEK293T cells. Figure 2A shows current traces recorded at
Vm in the range -80 to +65 mV from a holding potential of
-120 mV. Figure 2B shows the Vm dependence of the aver-
aged current density. The A551T mutation did not change
the shape of I-V curve, but significantly reduced the peak
current density (p < 0.01). To compare the inactivation
kinetics of the WT and A551T mutant, whole-cell currents
at various potentials were fitted to a bi-exponential func-
Twelve-lead ECG of the patient with Brugada syndrome. Figure 1
Twelve-lead ECG of the patient with Brugada syndrome.Journal of Biomedical Science 2009, 16:76 http://www.jbiomedsci.com/content/16/1/76
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Current density and inactivation kinetics of WT and A551T channels.   Figure 2
Current density and inactivation kinetics of WT and A551T channels.  A. Current traces recorded at Vm in the 
range -80 to +65 mV from a holding potential of -120 mV.  B. Averaged current density-Vm relationships.  C. Vm dependence 
of the inactivation time constants.  n = 18 for WT and 17 for A551T.  * p < 0.05; ** p < 0.01; *** p <0.005 vs. WT in this study.Journal of Biomedical Science 2009, 16:76 http://www.jbiomedsci.com/content/16/1/76
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tion. Figure 2C shows that both the fast (f, 0.5 – 4 ms)
and slow (s,  10 ms) inactivation time constants were
the same in the WT and A551T mutant, showing that the
A551T mutation did not affect the inactivation kinetics.
To examine whether the A551T mutation affected the Vm
dependence of channel activation, we next constructed
the normalized conductance-Vm relationship and found
that the Vm-dependent activation was the same in both
the WT channel and the A551T mutant (Fig 3A). However,
the V0.5 of the steady-state inactivation curve was shifted
from -87.7 ± 0.6 mV in the WT to -92.7 ± 0.7 mV in the
A551T mutant (p < 0.001) (Fig 3B), indicating enhanced
inactivation in the mutant.
It has previously been shown that some SCN5A mutations
associated with Brugada syndrome enhance the steady-
state inactivation of Nav1.5 channels by promoting the
entry of the channel into an intermediate inactivated state
[9,19,20]. To determine whether the A551T mutant had a
similar effect, we recorded the Vm dependence of the inter-
mediate inactivation state for the WT and A551T chan-
nels. Figure 3C shows that the fraction of channels
entering the intermediate inactivation state was the same
in the WT and A551T mutant at all Vm tested. We then
examined whether fast inactivation was affected by the
A551T mutation and found that it significantly shifted the
Vo.5 by -6 mV (Fig. 3C, V0.5 = -78 ± 1.4 in WT; -84.2 ± 1.7
in A551T; p < 0.05). It has previously been shown that
inactivation at a Vm < -60 mV occurs primarily via transi-
tions from the closed state [21]. Our results therefore sug-
gest that the A551T mutation enhances entry into fast
inactivation from the closed state.
Next, we studied whether recovery from inactivation was
affected by the A551T mutation. Recovery was first evalu-
ated at -120 mV after channels were activated and inacti-
vated at -20 mV. Figure 4A shows that the time-course of
recovery from inactivation were the same in the WT and
the A551T mutant. However, when recovery was recorded
at the physiological resting membrane potential, -90 mV,
the time constant of the A551T mutant was 73.6 ± 4.6 ms,
significantly larger than that of the WT (56.2 ± 4.4 ms, p <
0.05) (Fig. 4B). Furthermore, the percentage of channel
recovery was 23 ± 1% for the A551T mutant, significantly
lower than that for the WT (54 ± 2%, p < 0.001) (Fig. 4B).
According to the data in Figure 3B, 38 ± 3% of WT and 62
± 3% of A551T mutant channels entered the steady-state
inactivation state at a holding potential of -90 mV.
Together, the data show that 87% of WT and 61% of
A551T channels recovered from the inactivation induced
at +20 mV when recovery was examined at the physiolog-
ical resting membrane potential. These results suggest that
channel activity would decrease more in the A551T
mutant than the WT with repeated stimulation at a con-
stant frequency. In addition, due to the slower recovery
rate in the A551T mutant than in the WT, Nav1.5 channel
activity would be expected to decrease to a greater extent
at rapid stimulation rates in the mutant than in the WT. To
examine this hypothesis, we stimulated the WT and
mutant at 1 and 3 Hz. Figure 5A shows the current traces
recorded at the indicated frequency using a ramp protocol
to mimic the depolarization duration of a cardiac action
potential. As shown in Fig. 5B, when stimulated at 1 Hz,
channel current amplitude was only slightly decreased (10
± 2%) in the WT after 100 depolarizing ramp cycles, but
was decreased by 30 ± 3% in the A551T mutant (p = 6.4 ×
10-6, as compared to the value of the wild type), while the
corresponding decreases at 3 Hz were 78 ± 1% and 87 ±
2% (p = 0.007, as compared to the value of the wild type).
Note that a depolarizing ramp instead of an action poten-
tial waveform was used to voltage clamp the cells in exper-
iments described in Figure 5. Because the capacitance
transient overlapped with the peak of Na+ channels, it was
difficult to quantitate the peak Na+  current in action
potential clamp. However, since our purpose was to
examine the recovery of Na+ channels from inactivation
during the depolarization, the duration instead of shape
of the repolarization is important. Therefore, using the
depolarizing ramp protocol should not affect the conclu-
sion.
The effects of the A551T mutation are unlikely due to 
phosphorylation
As a first step to understanding the molecular mechanism
underlying the effect of A551T on the NAV1.5 channel, we
ran the kinase-specific eukaryotic protein phosphoylation
site-predicting program on the NetPhos 2.0 server and
found that A551T might be phosphorylated by casein
kinase II (probability = 0.55). To examine whether phos-
phorylation is involved in the effects of the A551T muta-
tion on the electrophysiological properties of Nav1.5
channels, we constructed the A551V and A551E mutants,
the rationale being that valine is a similar size to threo-
nine, but cannot be phosphorylated, whereas, if A551T is
indeed phosphorylated and the negative charges of the
phosphate are involved in the effects of the A551T
mutant, the A551E mutant might have similar effects on
Nav1.5 channels. Figure 6 shows that the A551 V mutant,
like the A551T mutant, shifted the Vm dependence of
steady-state inactivation (V0.5 = -92.4 ± 0.2 mV, p < 0.001
as compared to that of wild type, Fig 6A) and fast inacti-
vation (V0.5 = -84.6 ± 0.3 mV, p < 0.05 as compared to that
of wild type, Fig. 6B) to the left, whereas the A551E
mutant had no effect. These results strongly suggest that
the effect of the A551T mutation on the left shift of the Vm
dependence of fast inactivation is not associated with
phosphorylation at this site.Journal of Biomedical Science 2009, 16:76 http://www.jbiomedsci.com/content/16/1/76
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Current density and inactivation kinetics of WT and A551T channels Figure 3
Vm-dependent steady-state activation and inactivation of WT and A551T channels A. The normalized peak con-
ductance-Vm relationship. n = 22 for WT and 30 for A551T. B. Vm dependence of steady-state inactivation. Currents were nor-
malized to the maximum current recorded at the test Vm of -20 mV. k = 4.6 ± 0.1 and n = 24 for WT; k = 4.5 ± 0.1 and n = 19 
for A551T. C. Vmdependence of steady-state intermediate and fast inactivation. For fast inactivation, k = 8.1 ± 0.2 and n = 9 for 
WT; k = 7.9 ± 0.2 and n = 8 for A551T. For intermediate inactivation, k = 16.2 ± 1.9 and n = 10 for WT; k = 13.9 ± 2.1 and n 
= 10 for A551T. Insets: Vm protocols.Journal of Biomedical Science 2009, 16:76 http://www.jbiomedsci.com/content/16/1/76
Page 7 of 11
(page number not for citation purposes)
Time-course of recovery from inactivation. Figure 4
Time-course of recovery from inactivation. A. Normalized currents were obtained by dividing the current obtained at 
the P2 pulse by that obtained at the P1 pulse with a holding and interpulse potential of -120 mV. B. Time-course of recovery 
recorded with a holding and interpulse potential of -90 mV. Insets: Vm protocols (applied at 0.2 Hz). n = 7.Journal of Biomedical Science 2009, 16:76 http://www.jbiomedsci.com/content/16/1/76
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Effects of repeated stimulation on Na+ currents recorded from the wild-type and A551T mutant channels Figure 5
Effects of repeated stimulation on Na+ currents recorded from the wild-type and A551T mutant channels. A. 
Current traces recorded using the ramp protocol (inset) mimicking the action potential during the 1st, 10th, 50th, and 100th 
depolarization at the indicated stimulation frequency. B. Normalized peak currents during a train of depolarizing pulses. The 
currents were normalized to that obtained at the first pulse. n = 11 – 17. **, p < 0.01; ***, p < 0.001.
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Effects of the A551E and A551V mutations on the steady-state inactivation of Nav1.5 channels Figure 6
Effects of the A551E and A551V mutations on the steady-state inactivation of Nav1.5 channels. A. Vm depend-
ence of steady-state inactivation. k = 4.5 ± 0.1 and n = 19 for A551T; k = 5.2 ± 0.1 and n = 9 for A551V; k = 5.1 ± 0.1 and n = 
8 for A551E. B. Vm dependence of fast inactivation. k = 7.9 ± 0.2 and n = 8 for A551T; k = 8.5 ± 0.3 and n = 9 for A551V; k = 
8.9 ± 0.4 and n = 8 for A551E. Insets: Vm protocols (applied at 0.2 Hz).
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Discussion
Mutations in the SCN5A gene can cause heart diseases,
including Brugada syndrome, long QT syndrome, and iso-
lated atrioventricular conduction block [1,3,4,9,22,23].
Brugada syndrome is characterized by an elevated ST-seg-
ment in the right precordial ECG leads and is associated
with a high incidence of sudden death [6]. Previously, an
A551T mutation in the Nav1.5 channel was identified in
a proband with Brugada syndrome [16]. However, the
functional alteration caused by the A551T mutation and
its contribution to Brugada syndrome remain unknown.
In this study, we compared the electrophysiological prop-
erties of the WT and A551T mutant coexpressed with the
h1 subunit in HEK293T cells. We found that the current
density of the A551T mutant was smaller than that of the
WT. In addition, the A551T mutation increased the frac-
tion of channels entering fast inactivation from the closed
state at the resting membrane potential and decreased the
fraction, and rate, of channel recovery at -90 mV from
inactivation induced by depolarization. These changes in
electrophysiological properties caused by the A551T
mutation could potentially result in a significant decrease
in the Na+ current during phase 1 of the action potential
and thus a change in the action potential dome in the epi-
cardium, but not the endocardium, as the large transient
outward current in the epicardium would be unopposed.
This difference in changes in the dome would create a
transmural voltage gradient that may be responsible for
the ST-segment elevation associated with Brugada syn-
drome and might subsequently generate phase 2 reentrant
extrasystole, predisposing the patient to ventricular tachy-
cardia and ventricular fibrillation [24].
Stimulation frequency effects
Brugada syndrome is characterized by a high incidence of
sudden death in patients with structurally normal hearts
[6]. Our results showed that Nav1.5 channel activities
were dramatically reduced by the A551T mutation when
stimulated continuously at 1 Hz (normal heart rate). The
change in the action potential dome is critically depend-
ent on the fine balance of currents, including INa, Ito, and
ICa, that are elicited during phase 1 of the action potential
19. It has been shown that the ST-elevation in Brugada syn-
drome is frequency-dependent. For example, a premature
beat or faster pacing has been shown to restore the epicar-
dial dome (due to slower recovery of Ito from inactivation
at higher stimulation rates) and thus decrease the ST-seg-
ment elevation [24]. In addition, the ST level decreases
when the heart rate increases in patients with Brugada
syndrome [25]. Thus, although we showed that the A551T
mutation reduces Nav1.5 channel activity to a great extent
at a greater stimulation rate, the effects of exercise on the
patient remains unclear.
Role of the DI-DII linker in fast inactivation
An important finding in this study is that an Nav1.5 muta-
tion, A551T, in the cytoplasmic loop linking domains I
and II increased fast inactivation from the closed state and
reduced fractional, and rate, of channel recovery from
inactivation, suggesting that the DI-DII linker may be
involved in the fast inactivation gating process and its sta-
bility. The involvement of the DI-DII linker in regulating
fast inactivation has been shown previously. An L567Q
mutation of the Nav1.5 channel accelerates the inactiva-
tion kinetics of Nav1.5 currents and shifts the Vm depend-
ence of steady-state inactivation to the left [26]. In
addition, a G514C mutant accelerates inactivation kinet-
ics, but causes a positive shift in the Vm dependence of
steady-state inactivation [27]. Another mutant, L617F,
induces a positive shift in the Vm dependence of steady-
state inactivation [28]. These previous studies and our
present results provide evidence for a role of the cytoplas-
mic I-II linker in controlling the fast inactivation gate in
Na+ channels, a process that has been attributed to the
binding of the fast inactivation particle in the DIII-DIV
linker [29,30] to its docking sites in domains II-S4/S5 and
IV-S4/S5 [31-34]. In this study, our results further suggest
that the DI-DII linker may be involved in the regulation of
the stability of the fast inactivation. It remains to be deter-
mined whether the DI-DII linker interacts directly with
the fast inactivation particle or its docking sites, or allos-
terically regulates the inactivation gating process.
Conclusion
Electrophysiological characterization of the Nav1.5 muta-
tion, A551T, revealed that the cytoplasmic DI-DII linker
regulates fast inactivation and its recovery. The decreased
Nav1.5 activity caused by the A551T mutation supports
the hypothesis that a reduction in Nav1.5 function is
involved in the pathogenesis of Brugada syndrome. The
structural-functional study of the Nav1.5 channel
advances our understanding of its patho-physiolgocial
function and provides potential preventive and therapeu-
tic approaches to heart diseases.
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